Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350

1.

Proteome-based classification of Non-Muscle Invasive Bladder Cancer.

Stroggilos R, Mokou M, Latosinska A, Makridakis M, Lygirou V, Mavrogeorgis E, Drekolias D, Frantzi M, Mullen W, Fragkoulis C, Stasinopoulos K, Papadopoulos G, Stathouros G, Lazaris AC, Makrythanasis P, Ntoumas K, Mischak H, Zoidakis J, Vlahou A.

Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32556. [Epub ahead of print]

PMID:
31286493
2.

Urinary peptide panel for prognostic assessment of bladder cancer relapse.

Krochmal M, van Kessel KEM, Zwarthoff EC, Belczacka I, Pejchinovski M, Vlahou A, Mischak H, Frantzi M.

Sci Rep. 2019 May 21;9(1):7635. doi: 10.1038/s41598-019-44129-y.

3.

Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.

Ferreira JP, Verdonschot J, Collier T, Wang P, Pizard A, Bär C, Björkman J, Boccanelli A, Butler J, Clark A, Cleland JG, Delles C, Diez J, Girerd N, González A, Hazebroek M, Huby AC, Jukema W, Latini R, Leenders J, Levy D, Mebazaa A, Mischak H, Pinet F, Rossignol P, Sattar N, Sever P, Staessen JA, Thum T, Vodovar N, Zhang ZY, Heymans S, Zannad F.

Circ Heart Fail. 2019 May;12(5):e005897. doi: 10.1161/CIRCHEARTFAILURE.118.005897.

PMID:
31104495
4.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J.

Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16.

PMID:
31092909
5.

Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.

Schanstra JP, Luong TT, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, Alesutan I, Boehme B, Schelski N, Von Lewinski D, Mullen W, Nicklin S, Delles C, Feuillet G, Denis C, Lang F, Pieske B, Bascands JL, Mischak H, Saulnier-Blache JS, Voelkl J, Vlahou A, Klein J.

JCI Insight. 2019 May 16;4(10). pii: 125638. doi: 10.1172/jci.insight.125638. eCollection 2019 May 16.

6.

Peptidomics and proteomics based on CE-MS as a robust tool in clinical application: The past, the present, and the future.

Latosinska A, Siwy J, Mischak H, Frantzi M.

Electrophoresis. 2019 May 3. doi: 10.1002/elps.201900091. [Epub ahead of print] Review.

PMID:
31054149
7.

Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease.

Mokou M, Klein J, Makridakis M, Bitsika V, Bascands JL, Saulnier-Blache JS, Mullen W, Sacherer M, Zoidakis J, Pieske B, Mischak H, Roubelakis MG, Schanstra JP, Vlahou A.

EBioMedicine. 2019 Mar;41:91-104. doi: 10.1016/j.ebiom.2019.02.040. Epub 2019 Feb 28.

8.

Urinary proteome signature of Renal Cysts and Diabetes syndrome in children.

Ricci P, Magalhães P, Krochmal M, Pejchinovski M, Daina E, Caruso MR, Goea L, Belczacka I, Remuzzi G, Umbhauer M, Drube J, Pape L, Mischak H, Decramer S, Schaefer F, Schanstra JP, Cereghini S, Zürbig P.

Sci Rep. 2019 Feb 18;9(1):2225. doi: 10.1038/s41598-019-38713-5.

9.

Clinical Proteomics on the Path Toward Implementation: First Promises Delivered.

Frantzi M, Mischak H, Latosinska A.

Proteomics Clin Appl. 2019 Mar;13(2):e1800094. doi: 10.1002/prca.201800094. No abstract available.

PMID:
30767399
10.

Proteomics in Drug Development: The Dawn of a New Era?

Frantzi M, Latosinska A, Mischak H.

Proteomics Clin Appl. 2019 Mar;13(2):e1800087. doi: 10.1002/prca.201800087. Epub 2019 Feb 25. Review.

PMID:
30724014
11.

MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells.

Valiño-Rivas L, Cuarental L, Agustin M, Husi H, Cannata-Ortiz P, Sanz AB, Mischak H, Ortiz A, Sanchez-Niño MD.

Nephrol Dial Transplant. 2018 Dec 11. doi: 10.1093/ndt/gfy367. [Epub ahead of print]

PMID:
30541139
12.

Publisher Correction: Novel Urinary Biomarkers For Improved Prediction Of Progressive eGFR Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.

Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.

Sci Rep. 2018 Dec 10;8(1):17822. doi: 10.1038/s41598-018-36919-7.

13.

CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients.

Zürbig P, Mischak H, Menne J, Haller H.

Diabetes Care. 2019 Jan;42(1):e4-e5. doi: 10.2337/dc18-1322. Epub 2018 Nov 19. No abstract available.

PMID:
30455331
14.

Urinary proteomic biomarkers in oncology: ready for implementation?

Frantzi M, Latosinska A, Belczacka I, Mischak H.

Expert Rev Proteomics. 2019 Jan;16(1):49-63. doi: 10.1080/14789450.2018.1547193. Epub 2018 Nov 15.

PMID:
30412678
15.

Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.

Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.

Sci Rep. 2018 Oct 29;8(1):15940. doi: 10.1038/s41598-018-34386-8. Erratum in: Sci Rep. 2018 Dec 10;8(1):17822.

16.

Urinary proteomics to diagnose chronic active antibody-mediated rejection in pediatric kidney transplantation - a pilot study.

Kanzelmeyer NK, Zürbig P, Mischak H, Metzger J, Fichtner A, Ruszai KH, Seemann T, Hansen M, Wygoda S, Krupka K, Tönshoff B, Melk A, Pape L.

Transpl Int. 2019 Jan;32(1):28-37. doi: 10.1111/tri.13363. Epub 2018 Nov 12.

PMID:
30357927
17.

Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers.

Belczacka I, Pejchinovski M, Krochmal M, Magalhães P, Frantzi M, Mullen W, Vlahou A, Mischak H, Jankowski V.

Proteomics Clin Appl. 2019 May;13(3):e1800111. doi: 10.1002/prca.201800111. Epub 2018 Oct 18.

PMID:
30334612
18.

Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients.

Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL, Yang WY, Thijs L, Wei FF, Ciarka A, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.

PLoS One. 2018 Sep 24;13(9):e0204439. doi: 10.1371/journal.pone.0204439. eCollection 2018.

19.

Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.

Wallbach M, Zürbig P, Dihazi H, Müller GA, Wachter R, Beige J, Koziolek MJ, Mischak H.

J Clin Hypertens (Greenwich). 2018 Oct;20(10):1519-1526. doi: 10.1111/jch.13365. Epub 2018 Sep 10.

20.

The CKD plasma lipidome varies with disease severity and outcome.

Duranton F, Laget J, Gayrard N, Saulnier-Blache JS, Lundin U, Schanstra JP, Mischak H, Weinberger KM, Servel MF, Argilés A.

J Clin Lipidol. 2019 Jan - Feb;13(1):176-185.e8. doi: 10.1016/j.jacl.2018.07.010. Epub 2018 Aug 1.

PMID:
30177483
21.

Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

Latosinska A, Frantzi M, Merseburger AS, Mischak H.

Diagnostics (Basel). 2018 Aug 29;8(3). pii: E57. doi: 10.3390/diagnostics8030057. Review.

22.

Urinary peptidomic biomarkers of renal function in heart transplant recipients.

Huang QF, Zhang ZY, Van Keer J, Trenson S, Nkuipou-Kenfack E, Yang WY, Thijs L, Vanhaecke J, Van Aelst LNL, Van Cleemput J, Janssens S, Verhamme P, Mischak H, Staessen JA.

Nephrol Dial Transplant. 2018 Jul 2. doi: 10.1093/ndt/gfy185. [Epub ahead of print]

PMID:
29982668
23.

Proteomics biomarkers for solid tumors: Current status and future prospects.

Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M.

Mass Spectrom Rev. 2019 Jan;38(1):49-78. doi: 10.1002/mas.21572. Epub 2018 Jun 11. Review.

PMID:
29889308
24.

Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study.

Huang QF, Trenson S, Zhang ZY, Van Keer J, Van Aelst LNL, Yang WY, Nkuipou-Kenfack E, Thijs L, Wei FF, Mujaj B, Ciarka A, Droogné W, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.

Transplant Direct. 2018 Apr 23;4(5):e346. doi: 10.1097/TXD.0000000000000783. eCollection 2018 May.

25.

Clinical Proteomics: Closing the Gap from Discovery to Implementation.

Frantzi M, Latosinska A, Kontostathi G, Mischak H.

Proteomics. 2018 Jul;18(14):e1700463. doi: 10.1002/pmic.201700463. Epub 2018 Jul 8.

PMID:
29785737
26.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

Diabet Med. 2018 Oct;35(10):1375-1382. doi: 10.1111/dme.13669. Epub 2018 Jun 6.

PMID:
29781558
27.

Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction.

Zhang ZY, Nkuipou-Kenfack E, Yang WY, Wei FF, Cauwenberghs N, Thijs L, Huang QF, Feng YM, Schanstra JP, Kuznetsova T, Voigt JU, Verhamme P, Mischak H, Staessen JA.

J Am Soc Hypertens. 2018 Jun;12(6):438-447.e4. doi: 10.1016/j.jash.2018.03.007. Epub 2018 Mar 21.

28.

Clinical Proteomics in Kidney Disease: From Discovery to Clinical Application.

Pejchinovski M, Mischak H.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Dec 1;38(3):39-54. doi: 10.2478/prilozi-2018-0005.

PMID:
29668468
29.

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease.

Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A.

J Transl Med. 2018 Apr 17;16(1):104. doi: 10.1186/s12967-018-1476-9.

30.

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.

Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.

Cardiovasc Diabetol. 2018 Apr 6;17(1):50. doi: 10.1186/s12933-018-0697-9.

31.

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.

Sci Rep. 2018 Apr 3;8(1):5584. doi: 10.1038/s41598-018-22938-x.

32.

Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling.

Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.

Proteomics Clin Appl. 2018 Sep;12(5):e1700163. doi: 10.1002/prca.201700163. Epub 2018 Apr 23.

PMID:
29611317
33.

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y.

34.

Urinary peptidomics in kidney disease and drug research.

Krochmal M, Schanstra JP, Mischak H.

Expert Opin Drug Discov. 2018 Mar;13(3):259-268. doi: 10.1080/17460441.2018.1418320. Epub 2017 Dec 19. Review.

PMID:
29240457
35.

Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?

Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D, Rychlík I, Rroji M, Restivo A, Capasso G, Bob F, Schiller A, Ortiz A, Perez-Gomez MV, Cannata P, Sanchez-Niño MD, Naumovic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zürbig P, Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP.

Sci Rep. 2017 Dec 5;7(1):16915. doi: 10.1038/s41598-017-17083-w.

36.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

37.

Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.

Krochmal M, Kontostathi G, Magalhães P, Makridakis M, Klein J, Husi H, Leierer J, Mayer G, Bascands JL, Denis C, Zoidakis J, Zürbig P, Delles C, Schanstra JP, Mischak H, Vlahou A.

Sci Rep. 2017 Nov 9;7(1):15160. doi: 10.1038/s41598-017-15359-9.

38.

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome.

Cherney D, Perkins BA, Lytvyn Y, Heerspink H, Rodríguez-Ortiz ME, Mischak H.

PLoS One. 2017 Oct 30;12(10):e0186910. doi: 10.1371/journal.pone.0186910. eCollection 2017.

39.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

40.

Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients.

Markoska K, Pejchinovski M, Pontillo C, Zürbig P, Jacobs L, Smith A, Masin-Spasovska J, Stojceva-Taneva O, Polenakovic M, Magni F, Mischak H, Spasovski G.

Nephrol Dial Transplant. 2018 May 1;33(5):751-759. doi: 10.1093/ndt/gfx263.

PMID:
28992073
41.

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.

Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.

Proteomics Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700074. Epub 2017 Oct 25. Review.

PMID:
28980455
42.

A Urinary Fragment of Mucin-1 Subunit α Is a Novel Biomarker Associated With Renal Dysfunction in the General Population.

Zhang ZY, Ravassa S, Pejchinovski M, Yang WY, Zürbig P, López B, Wei FF, Thijs L, Jacobs L, González A, Voigt JU, Verhamme P, Kuznetsova T, Díez J, Mischak H, Staessen JA.

Kidney Int Rep. 2017 Sep;2(5):811-820. doi: 10.1016/j.ekir.2017.03.012.

43.

Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis.

Krochmal M, Cisek K, Filip S, Markoska K, Orange C, Zoidakis J, Gakiopoulou C, Spasovski G, Mischak H, Delles C, Vlahou A, Jankowski J.

Sci Rep. 2017 Aug 22;7(1):9091. doi: 10.1038/s41598-017-09393-w.

44.

A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin.

Voigtländer T, Metzger J, Schönemeier B, Jäger M, Mischak H, Manns MP, Lankisch TO.

United European Gastroenterol J. 2017 Aug;5(5):668-676. doi: 10.1177/2050640616687836. Epub 2017 Jan 11.

45.

Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure.

Zhang ZY, Ravassa S, Nkuipou-Kenfack E, Yang WY, Kerr SM, Koeck T, Campbell A, Kuznetsova T, Mischak H, Padmanabhan S, Dominiczak AF, Delles C, Staessen JA.

J Am Heart Assoc. 2017 Aug 7;6(8). pii: e005432. doi: 10.1161/JAHA.116.005432.

46.

Removal of Cell-Activating Substances Using Dialyzers With Various Permeability Profiles.

Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B.

Artif Organs. 2018 Jan;42(1):78-87. doi: 10.1111/aor.12952. Epub 2017 Jul 26.

PMID:
28744941
47.

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.

Pontillo C, Mischak H.

Clin Kidney J. 2017 Apr;10(2):192-201. doi: 10.1093/ckj/sfx002. Epub 2017 Mar 29.

48.

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Pejchinovski M, Siwy J, Mullen W, Mischak H, Petri MA, Burkly LC, Wei R.

Lupus. 2018 Jan;27(1):6-16. doi: 10.1177/0961203317707827. Epub 2017 May 5.

49.

Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology.

Wei R, Gao B, Shih F, Ranger A, Dearth A, Mischak H, Siwy J, Wisniacki N, Petri M, Burkly LC.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1468-1477. doi: 10.1093/ndt/gfw446.

PMID:
28339802
50.

Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?

Carleo A, Chorostowska-Wynimko J, Koeck T, Mischak H, Czajkowska-Malinowska M, Rozy A, Welte T, Janciauskiene S.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 8;12:829-837. doi: 10.2147/COPD.S125240. eCollection 2017.

Supplemental Content

Loading ...
Support Center